Alembic Pharmaceuticals announced that the United States Food and Drug Administration (US FDA) has conducted an inspection at Alembic Pharmaceuticals API Facility located at Panelav from April 16, 2018 to April 23, 2018. This was a scheduled inspection and at the end of the inspection, there were zero 483s.

The stock had underperformed the market over the past one month till Apr. 23, 2018, falling 6.11% compared with the Sensex's 5.69% rise. It underperformed the market in past one quarter, declining 8.04% as against 3.76% fall in the Sensex.

Shares of the company gained Rs 17.1, or 3.39%, to trade at Rs 521.05. The total volume of shares traded was 5,811 at the BSE (9.38 a.m., Tuesday).